6-mercaptopurine metabolite levels in children with inflammatory bowel disease

被引:73
作者
Gupta, P [1 ]
Gokhale, R [1 ]
Kirschner, BS [1 ]
机构
[1] Univ Chicago, Childrens Hosp, Dept Pediat, Sect Pediat Gastroenterol Hepatol & Nutr, Chicago, IL 60637 USA
关键词
inflammatory bowel disease; Crohn disease; 6-mercaptopurine; 6-thioguanine;
D O I
10.1097/00005176-200110000-00006
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives: Some authors suggest that efficacy of 6-mercaptopurine (6-MP) in patients with inflammatory bowel disease correlates with circulating 6-thioguanine (6-TG) levels more than 235 pmol/8 x 10(8) red blood cells. The authors evaluated the relation between 6-MP metabolite levels and disease activity in children and adolescents with inflammatory bowel disease. Methods: Clinical status and hematologic and hepatic parameters were determined in 101 children with inflammatory bowel diseasefrom a single center and compared with 6-MP metabolite levels. Results: There was a trend for higher 6-TG levels among patients in remission than among those with active disease (217 vs. 173); however the difference was not statistically significant (P = 0.09). The likelihood of therapeutic response did not increase significantly at 6-TG levels greater than 235 pmol/8 x 108 red blood cells (odds ratio 1.7; P = 0.1). In the current study, 58% of patients in remission had 6-TG levels less than 235. However, serial measurements of 6-MP metabolite levels in 50 patients with active disease showed that increasing 6-TG levels correlated significantly with disease remission in patients followed up longitudinally (P = 0.04). Leukopenia was significantly associated with high 6-TG levels (P = 0.03) but not with clinical response (P = 0.2). Conclusions: These data suggest that the target range of 6-TG levels previously described by others did not apply to 58% of the pediatric patients with IBD in remission. However, serial monitoring of 6-MP metabolite levels in individual patients with active disease should allow dose escalation and induction of remission while minimizing the risk of toxicity.
引用
收藏
页码:450 / 454
页数:5
相关论文
共 20 条
[1]  
COLONNA T, 1994, AM J GASTROENTEROL, V89, P362
[2]   BONE-MARROW TOXICITY CAUSED BY AZATHIOPRINE IN INFLAMMATORY BOWEL-DISEASE - 27 YEARS OF EXPERIENCE [J].
CONNELL, WR ;
KAMM, MA ;
RITCHIE, JK ;
LENNARDJONES, JE .
GUT, 1993, 34 (08) :1081-1085
[3]   6-Mercaptopurine metabolism in Crohn's disease: Correlation with efficacy and toxicity [J].
Cuffari, C ;
Theoret, Y ;
Latour, S ;
Seidman, G .
GUT, 1996, 39 (03) :401-406
[4]   Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease [J].
Dubinsky, MC ;
Lamothe, S ;
Yang, HY ;
Targan, SR ;
Sinnett, D ;
Théorêt, Y ;
Seidman, EG .
GASTROENTEROLOGY, 2000, 118 (04) :705-713
[5]   DEVELOPMENT AND VALIDATION OF A PEDIATRIC CROHNS-DISEASE ACTIVITY INDEX [J].
HYAMS, JS ;
FERRY, GD ;
MANDEL, FS ;
GRYBOSKI, JD ;
KIBORT, PM ;
KIRSCHNER, BS ;
GRIFFITHS, AM ;
KATZ, AJ ;
GRAND, RJ ;
BOYLE, JT ;
MICHENER, WM ;
LEVY, JS ;
LESSER, ML .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1991, 12 (04) :439-447
[6]   Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis [J].
Kader, HA ;
Mascarenhas, MR ;
Piccoli, DA ;
Stouffer, NO ;
Baldassano, RN .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1999, 28 (01) :54-58
[7]   Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease [J].
Kirschner, BS .
GASTROENTEROLOGY, 1998, 115 (04) :813-821
[8]   Clinical implications of thiopurine methyltransferase - Optimization of drug dosage and potential drug interactions [J].
Lennard, L .
THERAPEUTIC DRUG MONITORING, 1998, 20 (05) :527-531
[9]   CHILDHOOD LEUKEMIA - A RELATIONSHIP BETWEEN INTRACELLULAR 6-MERCAPTOPURINE METABOLITES AND NEUTROPENIA [J].
LENNARD, L ;
REES, CA ;
LILLEYMAN, JS ;
MADDOCKS, JL .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 16 (04) :359-363
[10]   Cross-sectional study of ibd patients taking azathioprine (AZA) or 6 mercaptopurine (6-MP): Lack of correlation between disease activity and 6 thioguanine nucleotide (6TGN) concentration. [J].
Lowry, PW ;
Franklin, CL ;
Weaver, AL ;
Pike, MG ;
Mays, DC ;
Tremaine, WJ ;
Lipsky, JJ ;
Sandborn, WJ .
GASTROENTEROLOGY, 2000, 118 (04) :A788-A788